Bevacizumab treatment for human glioblastoma. Can it induce cognitive impairment?

Recent results from 2 double-blind, placebo-controlled phase III trials (RTOG 0825) and (AVAglio) for first-line treatment of glioblastoma patients with the VEGF antibody bevacizumab, showed similar results, related to overall and progression-free survival. The RTOG 0825 trial indicated, opposed to...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Fathpour, Pakzad, Obad, Nina, Espedal, Heidi, Stieber, Daniel, Keunen, Olivier, Sakariassen, Per Ø., Niclou, Simone P., Bjerkvig, Rolf
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2014
Gaiak:
Letters to the Editor
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3984560/
https://ncbi.nlm.nih.gov/pubmed/24733853
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou013
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak